Online inquiry

IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12173MR)

This product GTTS-WQ12173MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12173MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7541MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ13920MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ3244MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ13031MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10241MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ4976MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ14004MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ10051MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW